Cargando…

393 Vancomycin Dosing in Obese Patients

Detalles Bibliográficos
Autores principales:	Alquwaizani, Mohammed, Kubiak, David W., Sansonetti, David, Barra, Megan, Calderwood, Michael S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	IDWeek 2014 Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5782357/ http://dx.doi.org/10.1093/ofid/ofu052.259

Ejemplares similares

An Evaluation of Systemic Vancomycin Dosing in Obese Patients
por: Kubiak, David W., et al.
Publicado: (2015)

192 Vancomycin Dosing in Obese and Morbidly Obese Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia
por: Morrill, Haley, et al.
Publicado: (2014)

675 Outcomes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) by vancomycin dosing regimen and vancomycin trough serum concentrations in the DISCOVER Program
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

678 Ceftaroline vs Vancomycin in Treatment for Skin and Soft Tissue Infections (SSTI) in Obese Patients
por: Nguyen, Hao, et al.
Publicado: (2014)

392 Vancomycin Dosing and Concentrations at a Large University-Affiliated County Hospital
por: Youn, Gilmer, et al.
Publicado: (2014)

288 Lack of Synergy With Six Blood Isolates of Methicillin-Resistant Staphylococcus aureus (Vancomycin MIC of 2) Tested With Combinations of Vancomycin + Gentamicin, Vancomycin + Rifampin and Vancomycin + Cefazolin.
por: Long, Virginia, et al.
Publicado: (2014)

396 What is the Best Predictor for Vancomycin Nephrotoxicity?
por: Hammoud, Kassem, et al.
Publicado: (2014)

673 Comparative Effectiveness of Vancomycin vs Early Daptomycin for MRSA Bacteremia with Vancomycin MIC >1 mg/L: A Multicenter Evaluation
por: Moise, Pamela, et al.
Publicado: (2014)

1652 Retrospective Comparision of Oral Vancomycin Capsules vs Oral Vancomycin Solution for the Treatment of Severe Clostridium Defficile Infection
por: Saleh, Rania, et al.
Publicado: (2014)

833 Lactobacillus GG (LGG) Does Not Eliminate Colonization by Vancomycin Resistant Enterococcus (VRE) in Adults with Comorbidities
por: Doron, Shira, et al.
Publicado: (2014)

394 Influence of febrile neutropenia on the pharmacokinetics and dosage requirements of vancomycin
por: Shiotsuka, Shouichi, et al.
Publicado: (2014)

1045 Linezolid Compared to Daptomycin for the Treatment of Vancomycin-resistant Enterococcal Urinary Tract Infections
por: Moenster, Ryan P., et al.
Publicado: (2014)

474 Ceftaroline Salvage Therapy for MRSA Bacteremia Following Vancomycin Failure
por: Pettit, Natasha, et al.
Publicado: (2014)

733 Vancomycin-Resistant Enterococcus (VRE) faecium Bloodstream Infections and Mortality
por: Suleyman, Geehan, et al.
Publicado: (2014)

688 The Effect of Preoperative Vancomycin on Bacteria Isolation from Operative Cultures
por: Young, Heather, et al.
Publicado: (2014)

757 Comparison of Nephrotoxicity in Outpatient Parenteral Antimicrobial Therapy (OPAT) Patients Receiving Beta-lactams or Vancomycin
por: Streifel, Amber, et al.
Publicado: (2014)

721 Decreasing Prevalence of Vancomycin-Heteroresistance (hVISA) among Methicillin-Resistant Staphylococcus aureus (MRSA) Blood Isolates over 10 years: Potential Impact of Vancomycin Treatment Guidelines
por: Khatib, Riad, et al.
Publicado: (2014)

915 Is a hospital's surgical site infection rate among Medicare-insured patients a good indicator of outcome for commercially-insured patients?
por: Calderwood, Michael S., et al.
Publicado: (2014)

1331 The SOLO Studies: A Single-Dose of Oritavancin (ORI) Compared to 7-10 Days of Vancomycin (VAN) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
por: Corey, Ralph, et al.
Publicado: (2014)

321 Screening Strategy to Detect Vancomycin-Resistant Enterococci Conversion in Exposed Roommates
por: Ng, Wil, et al.
Publicado: (2014)

409 Efficacy of Vancomycin against Biofilms of Neonatal Staphylococcus epidermidis Bloodstream Isolates
por: Simitsopoulou, Maria, et al.
Publicado: (2014)

322 Vancomycin-resistant Enterococci with Reduced Daptomycin Susceptibility in Singapore: Prevalence and Associated Factor
por: Chow, Angela, et al.
Publicado: (2014)

1796 Recovery of Clostridium difficile, Vancomycin Resistant Enterococcus and Methicillin Resistant Staphylococcus aureus from the Food of Hospitalized Patients
por: Kwon, Jennie H., et al.
Publicado: (2014)

1328 Decreased Vancomycin Use after Implementation of a Decision Support Program for Antibiotic Time Outs
por: Jones, Makoto, et al.
Publicado: (2014)

476 Heterogeneous Vancomycin-Intermediate Coagulase-Negative Staphylococci in Neonates: Does treatment with Linezolid improve outcomes?
por: Blanchard, Ana Chelène, et al.
Publicado: (2014)

236 Taking an Antibiotic Timeout: Utilizing an Antibiotic Renewal Template for Automatic Approval of Vancomycin and Piperacillin-tazobactam
por: Graber, Christopher J., et al.
Publicado: (2014)

271 Detection, evolution and outcome of the first case of Vancomycin Resistant Staphylococcus aureus (VRSA) infection in Europe
por: Melo-Cristino, Jose, et al.
Publicado: (2014)

266 Dalbavancin vs Vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

724 Vancomycin Minimum Inhibitory Concentration Does Not Predict Death, Recurrence or Readmission in Patients with Staphylococcus aureus Bacteremia in a Safety-Net Hospital
por: Baxi, Sanjiv, et al.
Publicado: (2014)

397 Correlation between calculated vancomycin AUC(0-24)/MIC and acute kidney injury in patients with Methicillin Resistant Staphylococcus Aureus bacteraemia
por: Ghosh, Niladri, et al.
Publicado: (2014)

395 Impact of vancomycin pharmacokinetic/pharmacodynamic data on clinical outcomes of methicillin-resistant Staphylococcus aureus bacteremia in children
por: Yoo, Reenar, et al.
Publicado: (2014)

1651 Role of Metronidazole vs Vancomycin as Initial Therapy in Hospitalized Patients with Mild to Moderate Clostridium difficile Infection (CDI) with NAP1 vs non-NAP1 Disease
por: Dubrovskaya, Yanina, et al.
Publicado: (2014)

728 Evaluation of Empirical Regimens Including Antistaphylococal Beta-lactam Antibiotics vs Vancomycin Monotherapy on Outcomes of Patients with Methicillin-Susceptible Staphylococcus aureus (MSSA) Bacteremia
por: Terico, Adrienne, et al.
Publicado: (2014)

908 Use of Claims Data to Identify Cases of Surgical Site Infection Following Colon Surgery Identified Many Unreported Infections in a State-Wide Validation
por: Calderwood, Michael S., et al.
Publicado: (2014)

907 Validation of Surgical Site Infection Data in California Hospitals Demonstrates Variable Case Identification Following Abdominal Hysterectomy
por: Calderwood, Michael S., et al.
Publicado: (2014)

408 The Comparison of in-vitro Activity of Daptomycin with Vancomycin and Teicoplanin against Methicillin-Resistant Staphylococcus aureus Strains Isolated from Bloodstream Infections
por: Demirdal, Tuna, et al.
Publicado: (2014)

799 Linezolid vs Vancomycin in the Treatment of Nosocomial Pneumonia: A Cost-effectiveness Analysis Incorporating Results from the ZEPHyR Trial
por: Collins, Curtis, et al.
Publicado: (2014)

331 Risk Factors for Vancomycin-resistant Enterococci and Carbapenemase-producing Carbapenem-resistant Enterobacteriaceae Colonization at admission to a Tertiary-care Center
por: Chow, Angela, et al.
Publicado: (2014)

280 Association between acessory gene regulator II expression and mortality among critically ill patients receiving vancomycin for hospital-acquired methicillin-resistant Staphylococcus aureus bacteremia
por: Rosa, Regis, et al.
Publicado: (2014)

473 Comparison of MicroScan System Prompt and Turbidity Methods for Measuring Vancomycin Minimum inhibitory concentration (MIC) against Methicillin-resistant Staphylococcus aureus (MRSA) with MIC of 2ug/ml, the Clinical Implications and economic impact of using alternative antimicrobial agents to vancomycin for MRSA with possible MIC of 2ug/ml
por: Kamran, Amir, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gggfm5k1ko3v0kacasb9sfdi45